C5aR1 | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

16 results for “C5aR1”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody

15 participants · First posted Sep 25, 2020

Not yet recruiting

Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target

66 participants · First posted Feb 21, 2024

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

73 participants · First posted Aug 15, 2024

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

60 participants · First posted May 30, 2014

Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )

208 participants · First posted May 1, 2020

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

73 participants · First posted Sep 11, 2018